## Pilar Brito-Zern

## List of Publications by Citations

Source: https://exaly.com/author-pdf/7667903/pilar-brito-zeron-publications-by-citations.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

108<br/>papers7,674<br/>citations45<br/>h-index87<br/>g-index117<br/>ext. papers9,292<br/>ext. citations5.1<br/>avg, IF5.95<br/>L-index

#	Paper	IF	Citations
108	Adult haemophagocytic syndrome. <i>Lancet, The</i> , <b>2014</b> , 383, 1503-1516	4O	698
107	Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 20-8	2.4	645
106	Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases. <i>Medicine (United States)</i> , <b>2007</b> , 86, 242-251	1.8	493
105	Sjigren syndrome. <i>Nature Reviews Disease Primers</i> , <b>2016</b> , 2, 16047	51.1	267
104	Autoimmune diseases induced by TNF-targeted therapies. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2008</b> , 22, 847-61	5.3	208
103	Hepatitis B virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-targeted therapy: analysis of 257 cases. <i>Medicine (United States)</i> , <b>2011</b> , 90, 359-371	1.8	203
102	The clinical spectrum of IgG4-related disease. <i>Autoimmunity Reviews</i> , <b>2014</b> , 13, 1203-10	13.6	192
101	Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2011</b> , 41, 256-64	5.3	190
100	Primary Sjogren syndrome. <i>BMJ, The</i> , <b>2012</b> , 344, e3821	5.9	166
99	Characterization of systemic disease in primary Sj\( \begin{alignet} \text{gren}'s syndrome: EULAR-SS Task Force recommendations for articular, cutaneous, pulmonary and renal involvements. \textit{Rheumatology}, \textbf{2015} , 54, 2230-8	3.9	150
98	EULAR Sjgren's syndrome disease activity index (ESSDAI): a user guide. <i>RMD Open</i> , <b>2015</b> , 1, e000022	5.9	150
97	Defining disease activity states and clinically meaningful improvement in primary Sjgren's syndrome with EULAR primary Sjgren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI). <i>Annals of the Rheumatic Diseases</i> , <b>2016</b> , 75, 382-9	2.4	144
96	The clinical spectrum of autoimmune congenital heart block. <i>Nature Reviews Rheumatology</i> , <b>2015</b> , 11, 301-12	8.1	140
95	Vasculitis in systemic lupus erythematosus: prevalence and clinical characteristics in 670 patients. <i>Medicine (United States)</i> , <b>2006</b> , 85, 95-104	1.8	140
94	EULAR recommendations for the management of Sjgren's syndrome with topical and systemic therapies. <i>Annals of the Rheumatic Diseases</i> , <b>2020</b> , 79, 3-18	2.4	139
93	Hypocomplementaemia as an immunological marker of morbidity and mortality in patients with primary Sjogren's syndrome. <i>British Journal of Rheumatology</i> , <b>2005</b> , 44, 89-94		136
92	Systemic involvement in primary Sjogren's syndrome evaluated by the EULAR-SS disease activity index: analysis of 921 Spanish patients (GEAS-SS Registry). <i>Rheumatology</i> , <b>2014</b> , 53, 321-31	3.9	125

## (2006-2012)

91	Topical and systemic medications for the treatment of primary Sjgren's syndrome. <i>Nature Reviews Rheumatology</i> , <b>2012</b> , 8, 399-411	8.1	123
90	Sarcoidosis in patients with chronic hepatitis C virus infection: analysis of 68 cases. <i>Medicine (United States)</i> , <b>2005</b> , 84, 69-80	1.8	123
89	Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival. <i>Lupus</i> , <b>2008</b> , 17, 281-8	2.6	120
88	Diagnostic Approach to the Complexity of IgG4-Related Disease. <i>Mayo Clinic Proceedings</i> , <b>2015</b> , 90, 927	-3694	119
87	Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors. <i>Rheumatology</i> , <b>2007</b> , 46, 1359-62	3.9	114
86	A systematic review of the off-label use of biological therapies in systemic autoimmune diseases. <i>Medicine (United States)</i> , <b>2008</b> , 87, 345-364	1.8	112
85	Systemic autoimmune diseases in patients with hepatitis C virus infection: characterization of 1020 cases (The HISPAMEC Registry). <i>Journal of Rheumatology</i> , <b>2009</b> , 36, 1442-8	4.1	107
84	Acute viral infections in patients with systemic lupus erythematosus: description of 23 cases and review of the literature. <i>Medicine (United States)</i> , <b>2008</b> , 87, 311-318	1.8	107
83	Therapeutic approach to IgG4-related disease: A systematic review. <i>Medicine (United States)</i> , <b>2016</b> , 95, e4002	1.8	103
82	Google-driven search for big data in autoimmune geoepidemiology: analysis of 394,827 patients with systemic autoimmune diseases. <i>Autoimmunity Reviews</i> , <b>2015</b> , 14, 670-9	13.6	96
81	The overlap of Sjgren's syndrome with other systemic autoimmune diseases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2007</b> , 36, 246-55	5.3	96
80	Atypical autoantibodies in patients with primary Sjgren syndrome: clinical characteristics and follow-up of 82 cases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2006</b> , 35, 312-21	5.3	84
79	Early diagnosis of primary Sjigren's syndrome: EULAR-SS task force clinical recommendations. <i>Expert Review of Clinical Immunology</i> , <b>2016</b> , 12, 137-56	5.1	83
78	IgG4-Related Disease: Results From a Multicenter Spanish Registry. <i>Medicine (United States)</i> , <b>2015</b> , 94, e1275	1.8	80
77	Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases. <i>Seminars in Arthritis and Rheumatism</i> , <b>2006</b> , 36, 189-96	5.3	78
76	Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 1255-1271	4.1	72
75	Thyroid disease in Sjgren's syndrome. <i>Clinical Rheumatology</i> , <b>2007</b> , 26, 1601-6	3.9	70
74	Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjgren's syndrome: prevalence and clinical significance in 335 patients. <i>Clinical Rheumatology</i> , <b>2006</b> , 25, 341-6	3.9	70

73	Systemic and organ-specific immune-related manifestations of COVID-19. <i>Nature Reviews Rheumatology</i> , <b>2021</b> , 17, 315-332	8.1	67
72	Characterization of B cell lymphoma in patients with Sjgren's syndrome and hepatitis C virus infection. <i>Arthritis and Rheumatism</i> , <b>2007</b> , 57, 161-70		62
71	Evidence-based recommendations on the management of extrahepatic manifestations of chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 1282-1299	13.4	58
70	Cardiovascular risk factors in primary Sjgren's syndrome: a case-control study in 624 patients. <i>Lupus</i> , <b>2010</b> , 19, 941-8	2.6	58
69	Monoclonal gammopathy related to Sjgren syndrome: a key marker of disease prognosis and outcomes. <i>Journal of Autoimmunity</i> , <b>2012</b> , 39, 43-8	15.5	55
68	Life-Threatening Cryoglobulinemic Patients With Hepatitis C: Clinical Description and Outcome of 279 Patients. <i>Medicine (United States)</i> , <b>2013</b> , 92, 273-284	1.8	53
67	Sarcoidosis or Sjgren syndrome? Clues to defining mimicry or coexistence in 59 cases. <i>Medicine</i> (United States), <b>2004</b> , 83, 85-95	1.8	53
66	Advances in the understanding and treatment of systemic complications in Sjgren's syndrome. <i>Current Opinion in Rheumatology</i> , <b>2014</b> , 26, 520-7	5.3	50
65	IgG4-related disease: Advances in the diagnosis and treatment. <i>Best Practice and Research in Clinical Rheumatology</i> , <b>2016</b> , 30, 261-278	5.3	49
64	Vasculitis induced by tumor necrosis factor-targeted therapies. <i>Current Rheumatology Reports</i> , <b>2008</b> , 10, 442-8	4.9	48
63	Outcomes in biopsy-proven lupus nephritis: evaluation of 190 white patients from a single center. <i>Medicine (United States)</i> , <b>2010</b> , 89, 300-307	1.8	41
62	Cryoglobulinaemic vasculitis at diagnosis predicts mortality in primary Sjgren syndrome: analysis of 515 patients. <i>Rheumatology</i> , <b>2016</b> , 55, 1443-51	3.9	41
61	Infection is the major trigger of hemophagocytic syndrome in adult patients treated with biological therapies. <i>Seminars in Arthritis and Rheumatism</i> , <b>2016</b> , 45, 391-9	5.3	40
60	Clinical and prognostic significance of parotid scintigraphy in 405 patients with primary Sjogren's syndrome. <i>Journal of Rheumatology</i> , <b>2010</b> , 37, 585-90	4.1	39
59	Emerging biological therapies in primary Sjogren's syndrome. Rheumatology, 2007, 46, 1389-96	3.9	39
58	Successful treatment of severe Raynaud's phenomenon with bosentan in four patients with systemic sclerosis. <i>British Journal of Rheumatology</i> , <b>2004</b> , 43, 1454-6		39
57	Primary Sjgren syndrome: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , <b>2013</b> , 14, 279-89	4	38
56	Association of mannose-binding lectin gene polymorphisms with antiphospholipid syndrome, cardiovascular disease and chronic damage in patients with systemic lupus erythematosus.  Rheumatology, 2007, 46, 76-80	3.9	38

## (2019-2007)

55	High prevalence of serum metabolic alterations in primary Sjgren's syndrome: influence on clinical and immunological expression. <i>Journal of Rheumatology</i> , <b>2007</b> , 34, 754-61	4.1	38
54	Circulating monoclonal immunoglobulins in Sjgren syndrome: prevalence and clinical significance in 237 patients. <i>Medicine (United States)</i> , <b>2005</b> , 84, 90-97	1.8	35
53	Rituximab therapy in lupus nephritis: current clinical evidence. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2011</b> , 40, 159-69	12.3	31
52	Treatment of B-cell lymphoma with rituximab in two patients with Sjgren's syndrome associated with hepatitis C virus infection. <i>Lupus</i> , <b>2004</b> , 13, 969-71	2.6	29
51	Prevalence and clinical relevance of autoimmune neutropenia in patients with primary Sj\(\bar{g}\)ren's syndrome. Seminars in Arthritis and Rheumatism, 2009, 38, 389-95	5.3	28
50	Sjgren syndrome or sjgren disease? The histological and immunological bias caused by the 2002 criteria. <i>Clinical Reviews in Allergy and Immunology</i> , <b>2010</b> , 38, 178-85	12.3	28
49	Clinically-useful serum biomarkers for diagnosis and prognosis of sarcoidosis. <i>Expert Review of Clinical Immunology</i> , <b>2019</b> , 15, 391-405	5.1	28
48	Haemophagocytic syndrome and COVID-19. Clinical Rheumatology, 2021, 40, 1233-1244	3.9	28
47	The Burden of Comorbidity and Complexity in Sarcoidosis: Impact of Associated Chronic Diseases. <i>Lung</i> , <b>2018</b> , 196, 239-248	2.9	28
46	Annular erythema in primary Sjogren's syndrome: description of 43 non-Asian cases. <i>Lupus</i> , <b>2014</b> , 23, 166-75	2.6	27
45	Chronic hepatitis B virus infection in Sjਊren's syndrome. Prevalence and clinical significance in 603 patients. <i>Autoimmunity Reviews</i> , <b>2009</b> , 8, 616-20	13.6	27
44	Anti-Ro52 antibody testing influences the classification and clinical characterisation of primary Sjgren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2012</b> , 30, 686-92	2.2	27
43	Sarcoidosis: an update on current pharmacotherapy options and future directions. <i>Expert Opinion on Pharmacotherapy</i> , <b>2016</b> , 17, 2431-2448	4	26
42	Complexity, comorbidity, and health care costs associated with chronic widespread pain in primary care. <i>Pain</i> , <b>2016</b> , 157, 818-826	8	26
41	Hepatitis C virus and Sjgren's syndrome: trigger or mimic?. <i>Rheumatic Disease Clinics of North America</i> , <b>2008</b> , 34, 869-84, vii	2.4	25
40	Characterization and differentiation of autoimmune versus viral liver involvement in patients with Sjgren's syndrome. <i>Journal of Rheumatology</i> , <b>2006</b> , 33, 1593-9	4.1	25
39	How hepatitis C virus modifies the immunological profile of Sjgren syndrome: analysis of 783 patients. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 250	5.7	24
38	Efficacy and safety of topical and systemic medications: a systematic literature review informing the EULAR recommendations for the management of Sjgren's syndrome. <i>RMD Open</i> , <b>2019</b> , 5, e001064	5.9	24

37	White matter abnormalities in primary Sjgren syndrome. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2012</b> , 105, 433-43	2.7	23
36	Systemic autoimmune diseases in elderly patients: atypical presentation and association with neoplasia. <i>Autoimmunity Reviews</i> , <b>2004</b> , 3, 376-82	13.6	22
35	Epidemiologic patterns of disease expression in sarcoidosis: age, gender and ethnicity-related differences. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 380-8	2.2	22
34	Cryoglobulinaemia associated with hepatitis C virus: influence of HCV genotypes, HCV-RNA viraemia and HIV coinfection. <i>Journal of Viral Hepatitis</i> , <b>2007</b> , 14, 736-42	3.4	20
33	Severe, life-threatening phenotype of primary Sjgren's syndrome: clinical characterisation and outcomes in 1580 patients (GEAS-SS Registry). <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 112, 121-129	2.2	20
32	Targeted therapy for systemic sclerosis: how close are we?. <i>Nature Reviews Rheumatology</i> , <b>2010</b> , 6, 269-	- <b>7</b> 881	18
31	Prognostic Factors of Death in 151 Adults With Hemophagocytic Syndrome: Etiopathogenically Driven Analysis. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , <b>2018</b> , 2, 267-276	3.1	17
30	Cytokines as therapeutic targets in primary Sjÿren syndrome. <i>Pharmacology &amp; Therapeutics</i> , <b>2018</b> , 184, 81-97	13.9	15
29	Mannose-binding lectin-low genotypes are associated with milder systemic and immunological disease expression in primary Sjigren's syndrome. <i>Rheumatology</i> , <b>2009</b> , 48, 65-9	3.9	15
28	Diagnosis of Liver Involvement in Primary Sjgren Syndrome. <i>Journal of Clinical and Translational Hepatology</i> , <b>2013</b> , 1, 94-102	5.2	15
27	Lessons from diseases mimicking Sj\(\mathbb{G}\)ren's syndrome. Clinical Reviews in Allergy and Immunology, <b>2007</b> , 32, 275-83	12.3	14
26	Classification and characterisation of peripheral neuropathies in 102 patients with primary Sjgren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2013</b> , 31, 103-10	2.2	14
25	How the Frequency and Phenotype of Sarcoidosis is Driven by Environmental Determinants. <i>Lung</i> , <b>2019</b> , 197, 427-436	2.9	13
24	Cryoglobulinemic disease. <i>Oncology</i> , <b>2013</b> , 27, 1098-1105, 1110-6	1.8	13
23	Geoepidemiological big data approach to sarcoidosis: geographical and ethnic determinants. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 1052-1064	2.2	13
22	Treating the Underlying Pathophysiology of Primary Sjgren Syndrome: Recent Advances and Future Prospects. <i>Drugs</i> , <b>2016</b> , 76, 1601-1623	12.1	12
21	Phenotyping Sjgren's syndrome: towards a personalised management of the disease. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 112, 198-209	2.2	12
20	Diagnosing unexplained fever: can quick diagnosis units replace inpatient hospitalization?. <i>European Journal of Clinical Investigation</i> , <b>2014</b> , 44, 707-18	4.6	10

19	Impact of a systematic evaluation of connective tissue disease on diagnosis approach in patients with interstitial lung diseases. <i>Medicine (United States)</i> , <b>2020</b> , 99, e18589	1.8	7
18	Introducing treat-to-target strategies of autoimmune extrahepatic manifestations of chronic hepatitis C virus infection. <i>Expert Review of Clinical Pharmacology</i> , <b>2017</b> , 10, 1085-1101	3.8	6
17	New approaches in Sjgren's syndrome therapy. Expert Review of Clinical Immunology, 2007, 3, 195-204	5.1	6
16	SjgrenB Syndrome: Beyond Sicca Involvement <b>2011</b> , 45-65		6
15	Etiopathogenic role of surfactant protein d in the clinical and immunological expression of primary Sjgren syndrome. <i>Journal of Rheumatology</i> , <b>2015</b> , 42, 111-8	4.1	5
14	Coexistence of immune-mediated diseases in sarcoidosis. Frequency and clinical significance in 1737 patients. <i>Joint Bone Spine</i> , <b>2021</b> , 88, 105236	2.9	4
13	Systemic manifestations of primary Sjgren's syndrome out of the ESSDAI classification: prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 118, 97-106	2.2	4
12	Autoimmune diseases in the elderly: systemic lupus erythematosus and Sjgren syndrome. <i>Aging Health</i> , <b>2008</b> , 4, 389-397		1
11	Systemic Therapy of Sjgren Syndrome. Rare Diseases of the Immune System, 2016, 383-398	0.2	1
10	Immunological Tests in Primary Sjÿren Syndrome <b>2011</b> , 401-416		1
9	Systemic phenotype related to primary Sjgren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 126, 85-94	2.2	1
8	Practical guidelines for the early diagnosis of Sjgren's syndrome in primary healthcare. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 197-205	2.2	1
7	Laboratory Abnormalities in Primary Sjgren Syndrome <b>2011</b> , 347-366		0
6	An update of targeted therapeutic options for primary Sjgren syndrome: current status and future development. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2359-2371	4	O
5	Punctal occlusion in Sjgren's syndrome needs clarification. <i>Nature Reviews Rheumatology</i> , <b>2012</b> , 8, 752-	7 <b>82</b> í	
4	Chapter 9 Adrenal Involvement in Systemic Autoimmune Diseases. <i>Handbook of Systemic Autoimmune Diseases</i> , <b>2008</b> , 9, 95-101	0.3	
3	Targeting B Cells in Other Systemic Autoimmune Diseases. <i>Milestones in Drug Therapy</i> , <b>2014</b> , 247-258		
2	Systemic Lupus Erythematosus: Indirect B-Cell Blocking. <i>Milestones in Drug Therapy</i> , <b>2014</b> , 79-95		

1 Sialadenitis **2021**, 48-63